Literature DB >> 3662475

Effect of roxithromycin on acute toxoplasmosis in mice.

H R Chang1, J C Pechere.   

Abstract

Roxithromycin effectively treated acute peritoneal murine toxoplasmosis. After five doses, starting 24 h after challenge, the 100 and 50% survival doses were 540 and 336 mg/kg per day, respectively. After 14 doses, starting 3 h after challenge, the 50% survival dose was 360 mg/kg per day. Toxoplasma gondii was recovered from the brain in 59 and 28% of surviving mice treated with 5 and 14 doses, respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662475      PMCID: PMC174888          DOI: 10.1128/AAC.31.7.1147

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  [Spiramycin therapy of experimental toxoplasmosis in mice].

Authors:  J P GARIN; D E EYLES
Journal:  Presse Med       Date:  1958-05-28       Impact factor: 1.228

Review 2.  Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature.

Authors:  R M Levy; D E Bredesen; M L Rosenblum
Journal:  J Neurosurg       Date:  1985-04       Impact factor: 5.115

3.  Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms.

Authors:  J Ruskin; J McIntosh; J S Remington
Journal:  J Immunol       Date:  1969-08       Impact factor: 5.422

4.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro.

Authors:  M T Labro; N Amit; C Babin-Chevaye; J Hakim
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Authors:  J Chan; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  The hematologic toxicity of pyrimethamine (daraprim) in man.

Authors:  H E KAUFMAN; P H GEISLER
Journal:  Arch Ophthalmol       Date:  1960-07

9.  The interaction between Toxoplasma gondii and mammalian cells. II. The absence of lysosomal fusion with phagocytic vacuoles containing living parasites.

Authors:  T C Jones; J G Hirsch
Journal:  J Exp Med       Date:  1972-11-01       Impact factor: 14.307

  9 in total
  10 in total

1.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Authors:  F G Araujo; D R Guptill; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

3.  The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.

Authors:  F G Araujo; A A Khan; T L Slifer; A Bryskier; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

4.  In vitro and in vivo effects of doxycycline on Toxoplasma gondii.

Authors:  H R Chang; R Comte; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 5.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

6.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.

Authors:  H R Chang; D Arsenijevic; R Comte; A Polak; R L Then; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

8.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 9.  Clinical relevance of intracellular and extracellular concentrations of macrolides.

Authors:  C Carbon
Journal:  Infection       Date:  1995       Impact factor: 3.553

10.  Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients.

Authors:  J Durant; F Hazime; M Carles; J C Pechere; P Dellamonica
Journal:  Infection       Date:  1995       Impact factor: 3.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.